Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma

被引：0
|
作者：
Wang, Q. [1 ]
Chai, X. [2 ]
Lin, R. [3 ]
Zheng, L. [4 ]
Cao, D. [5 ]
Qu, X. [6 ]
Liu, L. [7 ]
Wu, L. [8 ]
Mou, H. [9 ]
Xu, Q. [10 ]
Shi, J. [11 ]
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R China
[2] ChangSha TaiHe Hosp, Dept Oncol, Changsha, Peoples R China
[3] Fujian Canc Hosp, Dept Abdominal Oncol, Fujian, Peoples R China
[4] Sichuan Univ, West China Hosp, Clin Trial Ctr, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China
[6] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China
[7] Jilin Univ, China Japan Union Hosp, Phase Clin Trial Ctr 1, Changchun, Peoples R China
[8] Shulan Hangzhou Hosp, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
[9] Shulan Hangzhou Hosp, Dept Oncol, Hangzhou, Peoples R China
[10] Zhejiang Canc Hosp, Dept Hepatobiliary & Pancreat Gastroenterol, Hangzhou, Peoples R China
[11] Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.752
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
686TiP
引用
收藏
页码：S532 / S533
页数：2
相关论文
共 50 条
  • [1] A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models
    Mikami, Hirofumi
    Feng, Shu
    Naoi, Sotaro
    Azuma, Yumiko
    Kayukawa, Yoko
    Tsunenari, Toshiaki
    Asanuma, Kentaro
    Iwabuchi, Ryutaro
    Nagano, Hiroaki
    Shinozuka, Junko
    Yamazaki, Masaki
    Kuroi, Haruka
    Gan, Siok Wan
    Chichili, Priyanka
    Shimizu, Shun
    Matsuda, Yutaka
    Ishii, Shinya
    Kamikawaji, Shogo
    Kinoshita, Yasuko
    Shimizu, Yuichiro
    Sakamoto, Akihisa
    Muraoka, Masaru
    Takahashi, Noriyuki
    Kawa, Tatsuya
    Shiraiwa, Hirotake
    Kashima, Kenji
    Mimoto, Futa
    Kamata-Sakurai, Mika
    Kitazawa, Takehisa
    Igawa, Tomoyuki
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
    Wermke, Martin
    Felip, Enriqueta
    Gambardella, Valentina
    Kuboki, Yasutoshi
    Morgensztern, Daniel
    Hamed, Zohra Oum'
    Liu, Meiruo
    Studeny, Matus
    Owonikoko, Taofeek K.
    FUTURE ONCOLOGY, 2022, 18 (24) : 2639 - 2649
  • [3] FDA approves first DLL3 x CD3 bispecific T-cell engager for lung cancer
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (07) : 487 - 487
  • [4] First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)
    Wermke, Martin
    Felip, Enriqueta
    Kuboki, Yasutoshi
    Morgensztern, Daniel
    Sayehli, Cyrus
    Sanmamed, Miguel F.
    Arriola, Edurne
    Oum'Hamed, Zohra
    Song, Eric
    Studeny, Matus
    Gambardella, Valentina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas
    Gambardella, V.
    Castillon, J. Capdevila
    Kuboki, Y.
    Alese, O.
    Morgensztern, D.
    Sayehli, C. M.
    Sanmamed, M. F.
    Arriola, E.
    Hamed, Z. Oum'
    Song, E.
    Studeny, M.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S499 - S500
  • [6] Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC
    Wermke, M.
    Gambardella, V.
    Kuboki, Y.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C.
    Sanmamed, M. F.
    Arriola, E.
    Wolf, J.
    Villaruz, L.
    Studeny, M.
    Bouzaggou, M.
    Fang, X.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S32 - S32
  • [7] Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+tumors: Focus on Asian pts
    Kuboki, Y.
    Gambardella, V.
    Capdevila Castillon, J.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C. M.
    Sanmamed, M. F.
    Arriola, E.
    Wolf, J.
    Owonikoko, T. K.
    Studeny, M.
    Bouzaggou, M.
    Song, E.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1495 - S1495
  • [8] Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+Tumors: Focus on SCLC
    Wermke, M.
    Kuboki, Y.
    Felip, E.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C.
    Arriola, E.
    Sanmamed, M. F.
    Oum'Hamed, Z.
    Song, E.
    Studeny, M.
    Gambardella, V.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S45 - S46
  • [9] Screening and characterization of AlloCAR T targeting DLL3 for the treatment of small cell lung cancer
    Zhang, Yi
    Tacheva-Grigorova, Silvia
    Melton, Zea
    Smith, Bryan
    Sai, Tao
    Van Blarcom, Tom
    Amado, Rafael
    Sasu, Barbra
    Panowski, Siler
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Updated data from a phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumors: Focus on extrapulmonary neuroendocrine carcinomas (epNECs)
    Capdevila, J.
    Gambardella, V
    Kuboki, Y.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C.
    Sanmamed, M. F.
    Arriola, E.
    Wolf, J.
    Owonikoko, T.
    Studeny, M.
    Wermke, M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 227 - 227
12345